A reduced risk of stroke with lithium exposure in bipolar disorder: A population-based retrospective cohort study

Bipolar Disorders

Volumn 17, Issue 7, 2015, Pages 705-714

  Lan, Chen Chia ^a,b   Liu, Chia Chien ^b   Lin, Ching Heng ^c   Lan, Tzuo Yun ^b   McInnis, Melvin G ^d   Chan, Chin Hong ^c   Lan, Tsuo Hung ^b,c,e  

^a TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Bipolar disorder; Lithium; Neuroprotection; Risk; Stroke

Indexed keywords

LITHIUM SALT; LITHIUM DERIVATIVE; NEUROPROTECTIVE AGENT; PSYCHOTROPIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BIPOLAR DISORDER; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; FEMALE; HAZARD RATIO; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE; TAIWAN; TREATMENT RESPONSE; COMPLICATION; FACTUAL DATABASE; INCIDENCE; MIDDLE AGED; STROKE;

ADULT; BIPOLAR DISORDER; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROPORTIONAL HAZARDS MODELS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; STROKE; TAIWAN;

EID: 84945248375     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12336     Document Type: Article

References (43)

1. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg 2011; 76 (Suppl. 6): S85-S90.
2. Wu HC, Chou FH, Tsai KY, Su CY, Shen SP, Chung TC. The incidence and relative risk of stroke among patients with bipolar disorder: a seven-year follow-up study. PLoS ONE 2013; 8: e73037.
3. Lin HC, Tsai SY, Lee HC. Increased risk of developing stroke among patients with bipolar disorder after an acute mood episode: a six-year follow-up study. J Affect Disord 2007; 100: 49-54.
4. Prieto ML, Cuellar-Barboza AB, Bobo WV et al. Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis. Acta Psychiatr Scand 2014; 130: 342-353.
5. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352.
6. Van der Velde CD. Effectiveness of lithium carbonate in the treatment of manic-depressive illness. Am J Psychiatry 1970; 127: 345-351.
7. Bearden CE, Thompson PM, Dalwani M et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 2007; 62: 7-16.
8. Sassi RB, Nicoletti M, Brambilla P et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002; 329: 243-245.
9. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010; 62: 50-60.
10. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
11. Chuang DM, Wang Z, Chiu CT. GSK-3 as a Target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011; 4: 15.
12. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002; 43: 1173-1179.
13. Guo S, Arai K, Stins MF, Chuang DM, Lo EH. Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 2009; 40: 652-655.
14. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998; 95: 2642-2647.
15. Sarkar S, Floto RA, Berger Z et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005; 170: 1101-1111.
16. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. NeuroReport 1998; 9: 2081-2084.
17. Ren M, Senatorov VV, Chen RW, Chuang DM. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci USA 2003; 100: 6210-6215.
18. Xu J, Culman J, Blume A, Brecht S, Gohlke P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 2003; 34: 1287-1292.
19. Kang K, Kim YJ, Kim YH et al. Lithium pretreatment reduces brain injury after intracerebral hemorrhage in rats. Neurol Res 2012; 34: 447-454.
20. Yu F, Wang Z, Tchantchou F, Chiu CT, Zhang Y, Chuang DM. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J Neurotrauma 2012; 29: 362-374.
21. Mohammadianinejad SE, Majdinasab N, Sajedi SA, Abdollahi F, Moqaddam MM, Sadr F. The effect of lithium in post-stroke motor recovery: a double-blind, placebo-controlled, randomized clinical trial. Clin Neuropharmacol 2014; 37: 73-78.
22. Pelisek J, Eckstein HH, Zernecke A. Pathophysiological mechanisms of carotid plaque vulnerability: impact on ischemic stroke. Arch Immunol Ther Exp 2012; 60: 431-442.
23. De Meyer I, Martinet W, Van Hove CE et al. Inhibition of inositol monophosphatase by lithium chloride induces selective macrophage apoptosis in atherosclerotic plaques. Br J Pharmacol 2011; 162: 1410-1423.
24. Choi SE, Jang HJ, Kang Y et al. Atherosclerosis induced by a high-fat diet is alleviated by lithium chloride via reduction of VCAM expression in ApoE-deficient mice. Vascul Pharmacol 2010; 53: 264-272.
25. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-635.
26. Kim S, Bong N, Kim OS, Jin J, Kim DE, Lee DK. Lithium chloride suppresses LPS-mediated matrix metalloproteinase-9 expression in macrophages through phosphorylation of GSK-3beta. Cell Biol Int 2015; 39: 177-184.
27. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res 2012; 95: 194-204.
28. Ho-Tin-Noe B, Michel JB. Initiation of angiogenesis in atherosclerosis: smooth muscle cells as mediators of the angiogenic response to atheroma formation. Trends Cardiovasc Med 2011; 21: 183-187.
29. Wang Z, Zhang X, Chen S et al. Lithium chloride inhibits vascular smooth muscle cell proliferation and migration and alleviates injury-induced neointimal hyperplasia via induction of PGC-1alpha. PLoS ONE 2013; 8: e55471.
30. Xu J, Scholz A, Rosch N et al. Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats. J Hypertens 2005; 23: 2277-2285.
31. National Health Insurance Database. Sampling method of database subset (in Chinese). Available from: http://nhird.nhri.org.tw/date_cohort.html [accessed July 2015].
32. Rej S, Beaulieu S, Segal M et al. Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life. Drugs Aging 2014; 31: 911-916.
33. Hsieh FI, Chiou HY. Stroke: morbidity, risk factors, and care in taiwan. J Stroke 2014; 16: 59-64.
34. El Husseini N, Kaskar O, Goldstein LB. Chronic kidney disease and stroke. Adv Chronic Kidney Dis 2014; 21: 500-508.
35. Dong JY, Zhang YH, Tong J, Qin LQ. Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 2012; 43: 32-37.
36. Tsai KY, Lee CC, Chou YM, Su CY, Chou FH. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. Schizophr Res 2012; 138: 41-47.
37. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-1115.
38. Hsieh PH, Hsiao FY, Gau SS, Gau CS. Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study. J Clin Psychopharmacol 2013; 33: 299-305.
39. Franchi C, Sequi M, Tettamanti M et al. Antipsychotics prescription and cerebrovascular events in Italian older persons. J Clin Psychopharmacol 2013; 33: 542-545.
40. Laredo L, Vargas E, Blasco AJ, Aguilar MD, Moreno A, Portoles A. Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study. J Am Geriatr Soc 2011; 59: 1182-1187.
41. Percudani M, Barbui C, Fortino I, Tansella M, Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 2005; 25: 468-470.
42. Olesen JB, Abildstrom SZ, Erdal J et al. Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. Pharmacoepidemiol Drug Saf 2011; 20: 964-971.
43. Chang CS, Liao CH, Lin CC, Lane HY, Sung FC, Kao CH. Patients with epilepsy are at an increased risk of subsequent stroke: a population-based cohort study. Seizure 2014; 23: 377-381.